Related Experiment Video

Updated: Aug 8, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

The management of hypertension in ischaemic heart disease

Nathaniel M Hawkins1, Francis G Dunn

  • 1Cardiology Department, Stobhill Hospital, Glasgow, UK.

Current Opinion in Cardiology
|June 7, 2006
PubMed

Insights

Managing hypertension and coronary artery disease requires comprehensive risk factor reduction. Achieving blood pressure targets and intensive lipid lowering are crucial for improving patient outcomes and cardiovascular health.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Hypertension and coronary artery disease (CAD) frequently coexist and are often undertreated, with many patients failing to reach target blood pressure levels.
  • A significant gap exists between evidence-based guidelines and clinical practice regarding the implementation of effective drug therapies for these conditions.

Purpose of the Study:

  • To review current evidence on optimizing treatment strategies for patients with both hypertension and CAD.
  • To highlight the importance of comprehensive cardiovascular risk factor management beyond blood pressure control.

Main Methods:

  • Review of recent clinical trials and guidelines focusing on antihypertensive and lipid-lowering therapies.
  • Analysis of the comparative effectiveness and recommended use of different drug classes.

Main Results:

  • Blood pressure reduction remains paramount, though the superiority of specific agents like ACE inhibitors and beta-blockers is debated; calcium channel blockers show increasing recognition.
  • All major drug classes (ACE inhibitors, beta-blockers, calcium channel blockers) are often necessary to achieve blood pressure goals.
  • Statin therapy for intensive lipid lowering is a critical intervention, with greater reductions in low-density lipoprotein cholesterol linked to further decreases in cardiovascular events.
  • Lifestyle modifications, including smoking cessation, exercise, and diet, are often underestimated but vital components of risk reduction.

Conclusions:

  • Optimal patient prognosis hinges on reducing global cardiovascular risk through aggressive management of all modifiable factors.
  • Blood pressure reduction, utilizing agents with both antihypertensive and antianginal effects, is a cornerstone of treatment for patients with hypertension and CAD.
Abstract

Related Concept Videos

Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...